Boxer Capital Management
Latest statistics and disclosures from Boxer Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TNGX, RVMD, KOD, KYMR, CELC, and represent 45.53% of Boxer Capital Management's stock portfolio.
- Added to shares of these 10 stocks: TERN (+$15M), PRAX (+$14M), CELC (+$14M), PALI (+$11M), KOD (+$11M), TNGX (+$9.8M), SRZN (+$9.4M), CAPR (+$9.4M), COGT (+$8.0M), HELP (+$5.8M).
- Started 15 new stock positions in CTNM, CLNN, GPCR, SRZN, KPTI, PRAX, TERN, IVVD, VIR, ZURA. UPB, PALI, CAPR, HELP, COGT.
- Reduced shares in these 10 stocks: QURE (-$12M), MRUS (-$11M), NKTR (-$7.1M), CYTK (-$6.4M), DNLI, REPL, SRPT, URGN, SLDB, NRIX.
- Sold out of its positions in DNLI, TIL, NKTR, MRUS.
- Boxer Capital Management was a net buyer of stock by $101M.
- Boxer Capital Management has $457M in assets under management (AUM), dropping by 45.63%.
- Central Index Key (CIK): 0002018299
Tip: Access up to 7 years of quarterly data
Positions held by Boxer Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Boxer Capital Management
Boxer Capital Management holds 45 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Tango Therapeutics (TNGX) | 21.1 | $96M | +11% | 11M | 8.86 |
|
| Revolution Medicines (RVMD) | 7.0 | $32M | 400k | 79.65 |
|
|
| Kodiak Sciences (KOD) | 7.0 | $32M | +51% | 1.1M | 27.96 |
|
| Kymera Therapeutics (KYMR) | 5.6 | $26M | +3% | 329k | 77.81 |
|
| Celcuity (CELC) | 4.9 | $22M | +150% | 225k | 99.74 |
|
| Abivax Sa Sponsored Ads (ABVX) | 3.7 | $17M | +4% | 125k | 134.85 |
|
| Ptc Therapeutics I (PTCT) | 3.3 | $15M | 200k | 75.96 |
|
|
| Terns Pharmaceuticals (TERN) | 3.3 | $15M | NEW | 375k | 40.40 |
|
| Protagonist Therapeutics (PTGX) | 3.2 | $15M | +54% | 170k | 87.34 |
|
| Praxis Precision Medicines I Com New (PRAX) | 3.0 | $14M | NEW | 47k | 294.74 |
|
| Urogen Pharma (URGN) | 2.6 | $12M | -13% | 500k | 23.42 |
|
| Cidara Therapeutics Com New (CDTX) | 2.6 | $12M | +10% | 53k | 220.89 |
|
| Palisade Bio (PALI) | 2.5 | $11M | NEW | 4.8M | 2.35 |
|
| Amylyx Pharmaceuticals (AMLX) | 2.1 | $9.7M | -11% | 800k | 12.08 |
|
| Surrozen Com New (SRZN) | 2.1 | $9.4M | NEW | 416k | 22.60 |
|
| Capricor Therapeutics Com New (CAPR) | 2.1 | $9.4M | NEW | 325k | 28.86 |
|
| Mind Medicine Mindmed Com New (MNMD) | 1.8 | $8.0M | +266% | 599k | 13.39 |
|
| Cogent Biosciences (COGT) | 1.7 | $8.0M | NEW | 225k | 35.52 |
|
| Replimune Group (REPL) | 1.6 | $7.3M | -28% | 750k | 9.72 |
|
| Uniqure Nv SHS (QURE) | 1.5 | $6.9M | -63% | 290k | 23.93 |
|
| Cytokinetics Com New (CYTK) | 1.4 | $6.4M | -50% | 100k | 63.54 |
|
| Cybin Com New (HELP) | 1.3 | $5.8M | NEW | 715k | 8.18 |
|
| Precigen (PGEN) | 1.3 | $5.7M | +61% | 1.4M | 4.18 |
|
| Contineum Therapeutics Cl A (CTNM) | 1.2 | $5.6M | NEW | 494k | 11.43 |
|
| Crescent Biopharma (CBIO) | 1.2 | $5.4M | 454k | 11.86 |
|
|
| Apogee Therapeutics (APGE) | 1.2 | $5.3M | +40% | 70k | 75.48 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.1 | $5.2M | NEW | 75k | 69.55 |
|
| Avalo Therapeutics Com New (AVTX) | 1.1 | $5.0M | +120% | 275k | 18.16 |
|
| Inovio Pharmaceuticals Com Shs (INO) | 0.9 | $4.2M | +5% | 2.4M | 1.74 |
|
| Upstream Bio (UPB) | 0.9 | $4.1M | NEW | 150k | 27.15 |
|
| Vir Biotechnology (VIR) | 0.8 | $3.8M | NEW | 625k | 6.03 |
|
| Adagio Therapeutics (IVVD) | 0.8 | $3.7M | NEW | 1.5M | 2.47 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.8 | $3.6M | +10% | 275k | 13.18 |
|
| Sarepta Therapeutics (SRPT) | 0.7 | $3.2M | -40% | 150k | 21.52 |
|
| Pepgen (PEPG) | 0.5 | $2.4M | +49% | 374k | 6.51 |
|
| Nurix Therapeutics (NRIX) | 0.4 | $1.9M | -42% | 100k | 18.97 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.4 | $1.9M | NEW | 253k | 7.36 |
|
| Solid Biosciences Com New (SLDB) | 0.4 | $1.7M | -50% | 300k | 5.64 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 0.3 | $1.6M | 70k | 22.26 |
|
|
| Milestone Pharmaceuticals (MIST) | 0.3 | $1.3M | 667k | 2.02 |
|
|
| Clene Com New (CLNN) | 0.3 | $1.2M | NEW | 200k | 5.87 |
|
| Kalvista Pharmaceuticals (KALV) | 0.1 | $330k | 20k | 16.15 |
|
|
| Zura Bio Class A Ord Shs (ZURA) | 0.1 | $262k | NEW | 50k | 5.24 |
|
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 0.0 | $88k | 267k | 0.33 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $1.3k | 67k | 0.02 |
|
Past Filings by Boxer Capital Management
SEC 13F filings are viewable for Boxer Capital Management going back to 2024
- Boxer Capital Management 2025 Q1 restated filed Feb. 17, 2026
- Boxer Capital Management 2025 Q2 restated filed Feb. 17, 2026
- Boxer Capital Management 2025 Q3 restated filed Feb. 17, 2026
- Boxer Capital Management 2025 Q4 filed Feb. 17, 2026
- Boxer Capital Management 2025 Q3 filed Nov. 14, 2025
- Boxer Capital Management 2025 Q2 filed Aug. 14, 2025
- Boxer Capital Management 2025 Q1 filed May 15, 2025
- Boxer Capital Management 2024 Q4 filed Feb. 14, 2025